Embryonic stem cell therapy closer to human trials

November 19, 2009 by Mira Oberman

Embryonic stem cell therapy got a step closer to the clinic Thursday after US researchers said they filed a request for government approval of human trials.

The trials would involve 12 patients losing their sight to a currently untreatable disease called Stargardt, which is one of the most common forms of juvenile blindness.

The treatment would consist of a single injection of retinal cells derived from .

Previous studies in rats and mice have found that the treatment prevented further vision loss without adverse side effects, said Robert Lanza, the chief scientific officer at Advanced Cell Technology.

It works by replacing lost retinal cells -- called retinal pigment epithelium (RPE) -- which maintain the photoreceptors needed for vision.

"If you start to lose these RPE, the environment for the photoreceptors degenerates," Lanza said in a telephone interview.

"By putting these RPEs back in you can prevent the loss of these photoreceptors and prevent blindness."

The trials could begin as early as the beginning of next year if the Food and Drug Administration grants approval, Lanza said.

This is just the second proposal for a clinical trial of embryonic stem cell therapies that has been submitted for approval, he added.

The other project, which would address , has been placed on hold and is not expected to begin before the third quarter of 2010, according to a recent press release from California-based Geron.

"After years of research and political debate, we're finally on the verge of showing the potential clinical value of embryonic stem cells," Lanza said.

"The field desperately needs a big clinical success."

Embryonic is controversial because are destroyed in order to obtain the primitive cells capable of developing into almost every tissue of the body.

But it also holds great promise for treating cancer, diabetes, Alzheimer's and other diseases and even growing transplantable organs and tissues.

Researchers have found a way to sidestep both the controversy and the difficulty of working with embryonic stem cells by reprogramming ordinary skin cells into stem cells.

But this method is still so new that it could take years to replicate the experiments already done with embryonic stem cells and build up similar banks of tested cell lines, Lanza said.

"That is not a substitute certainly in the next several years for embryonic ," he said.

The Massachusetts-based company will be seeking approval for a human trial using similar methods to treat age-related macular degeneration, Lanza added.

(c) 2009 AFP

Related Stories

Recommended for you

Make way for hemoglobin

August 18, 2017
Every cell in the body, whether skin or muscle or brain, starts out as a generic cell that acquires its unique characteristics after undergoing a process of specialization. Nowhere is this process more dramatic than it is ...

Bio-inspired materials give boost to regenerative medicine

August 18, 2017
What if one day, we could teach our bodies to self-heal like a lizard's tail, and make severe injury or disease no more threatening than a paper cut?

Are stem cells the link between bacteria and cancer?

August 17, 2017
Gastric carcinoma is one of the most common causes of cancer-related deaths, primarily because most patients present at an advanced stage of the disease. The main cause of this cancer is the bacterium Helicobacter pylori, ...

Two-step process leads to cell immortalization and cancer

August 17, 2017
A mutation that helps make cells immortal is critical to the development of a tumor, but new research at the University of California, Berkeley suggests that becoming immortal is a more complicated process than originally ...

Female mouse embryos actively remove male reproductive systems

August 17, 2017
A protein called COUP-TFII determines whether a mouse embryo develops a male reproductive tract, according to researchers at the National Institutes of Health and their colleagues at Baylor College of Medicine, Houston. The ...

New Pathology Atlas maps genes in cancer to accelerate progress in personalized medicine

August 17, 2017
A new Pathology Atlas is launched today with an analysis of all human genes in all major cancers showing the consequence of their corresponding protein levels for overall patient survival. The difference in expression patterns ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.